Kinnate Biopharma Inc
F:6KB
Cash Flow Statement
Cash Flow Statement
Kinnate Biopharma Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||||||
| Net Income |
(36)
|
(53)
|
(75)
|
(77)
|
(90)
|
(99)
|
(105)
|
(111)
|
(116)
|
(122)
|
(127)
|
(127)
|
(113)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Stock-Based Compensation |
2
|
5
|
9
|
12
|
15
|
17
|
18
|
19
|
20
|
20
|
21
|
21
|
0
|
|
| Other Non-Cash Items |
2
|
6
|
10
|
13
|
17
|
19
|
20
|
20
|
20
|
20
|
19
|
18
|
16
|
|
| Change in Working Capital |
3
|
4
|
4
|
2
|
2
|
1
|
(0)
|
2
|
6
|
6
|
6
|
2
|
(4)
|
|
| Cash from Operating Activities |
(30)
N/A
|
(44)
-45%
|
(61)
-40%
|
(62)
-2%
|
(71)
-14%
|
(79)
-11%
|
(85)
-8%
|
(88)
-4%
|
(89)
-1%
|
(96)
-7%
|
(102)
-6%
|
(106)
-5%
|
(100)
+6%
|
|
| Investing Cash Flow | ||||||||||||||
| Capital Expenditures |
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(3)
|
(3)
|
(3)
|
(3)
|
(1)
|
(0)
|
(0)
|
0
|
|
| Other Items |
(31)
|
(201)
|
(233)
|
(214)
|
(180)
|
(73)
|
(17)
|
(19)
|
(4)
|
114
|
79
|
105
|
110
|
|
| Cash from Investing Activities |
(32)
N/A
|
(201)
-535%
|
(233)
-16%
|
(214)
+8%
|
(181)
+16%
|
(76)
+58%
|
(20)
+73%
|
(22)
-9%
|
(7)
+69%
|
113
N/A
|
79
-30%
|
105
+32%
|
110
+5%
|
|
| Financing Cash Flow | ||||||||||||||
| Net Issuance of Common Stock |
351
|
351
|
352
|
254
|
2
|
2
|
2
|
2
|
2
|
1
|
2
|
2
|
1
|
|
| Other |
(0)
|
(0)
|
35
|
35
|
35
|
0
|
(0)
|
(0)
|
(0)
|
(10)
|
(10)
|
(10)
|
(9)
|
|
| Cash from Financing Activities |
351
N/A
|
351
N/A
|
386
+10%
|
289
-25%
|
36
-87%
|
36
+0%
|
2
-96%
|
2
N/A
|
1
-24%
|
(8)
N/A
|
(7)
+7%
|
(8)
-2%
|
(8)
-2%
|
|
| Change in Cash | ||||||||||||||
| Effect of Foreign Exchange Rates |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
|
| Net Change in Cash |
289
N/A
|
106
-63%
|
92
-13%
|
13
-86%
|
(215)
N/A
|
(118)
+45%
|
(104)
+12%
|
(108)
-5%
|
(95)
+13%
|
9
N/A
|
(30)
N/A
|
(9)
+69%
|
2
N/A
|
|
| Free Cash Flow | ||||||||||||||
| Free Cash Flow |
(30)
N/A
|
(44)
-44%
|
(61)
-40%
|
(62)
-1%
|
(72)
-15%
|
(82)
-13%
|
(88)
-8%
|
(91)
-3%
|
(92)
-1%
|
(96)
-5%
|
(102)
-6%
|
(107)
-5%
|
(100)
+6%
|
|